The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - A pilot study

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 2, 2012, Pages 255-265

  Martin, C R ^a   Blanco, P G ^a   Keach, J C ^b   Petz, J L ^b   Zaman, M M ^a   Bhaskar, K R ^a   Cluette Brown, J E ^a   Gautam, S ^a   Sheth, S ^a   Afdhal, N H ^a   Lindor, K D ^b   Freedman, S D ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; DOCOSAHEXAENOIC ACID; GAMMA GLUTAMYLTRANSFERASE; HYALURONIC ACID; MESALAZINE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; URSODEOXYCHOLIC ACID;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIVER FIBROSIS; LIVER FUNCTION TEST; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PILOT STUDY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; SCORING SYSTEM; SUPPLEMENTATION; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; ALKALINE PHOSPHATASE; BILE DUCTS; BIOLOGICAL MARKERS; CHOLANGITIS, SCLEROSING; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; FEMALE; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 83855162140     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04926.x     Document Type: Article

References (23)

1. Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-14.
2. El Fouly A, Dechene A, Gerken G,. Surveillance and screening of primary sclerosing cholangitis. Dig Dis 2009; 27: 526-35.
3. Franco J, Saeian K,. Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis. Curr Gastroenterol Rep 1999; 1: 95-101.
4. McLoughlin M, Enns R,. Endoscopy in the management of primary sclerosing cholangitis. Curr Gastroenterol Rep 2008; 10: 177-85.
5. Sheth S, Shea JC, Bishop MD, et al. Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum Genet 2003; 113: 286-92. (Pubitemid 36992289)
6. Pall H, Zielenski J, Jonas MM, et al. Primary sclerosing cholangitis in childhood is associated with abnormalities in cystic fibrosis-mediated chloride channel function. J Pediatr 2007; 151: 255-9. (Pubitemid 47284133)
7. Cohn JA, Strong TV, Picciotto MR, Nairn AC, Collins FS, Fitz JG,. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology 1993; 105: 1857-64. (Pubitemid 24002805)
8. Gaskin KJ, Waters DL, Howman-Giles R, et al. Liver disease and common-bile-duct stenosis in cystic fibrosis. N Engl J Med 1988; 318: 340-6. (Pubitemid 18044162)
9. Freedman SD, Weinstein D, Blanco PG, et al. Characterization of LPS-induced lung inflammation in cftr-/- mice and the effect of docosahexaenoic acid. J Appl Physiol 2002; 92: 2169-76. (Pubitemid 34666448)
10. Karp CL, Flick LM, Park KW, et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004; 5: 388-92. (Pubitemid 38500087)
11. Zaman MM, Gelrud A, Junaidi O, et al. Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered. Clin Diagn Lab Immunol 2004; 11: 819-24. (Pubitemid 39280584)
12. Freedman SD, Blanco PG, Zaman MM, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004; 350: 560-9. (Pubitemid 38160786)
13. Freedman SD, Katz MH, Parker EM, Laposata M, Urman MY, Alvarez JG,. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice. Proc Natl Acad Sci U S A 1999; 96: 13995-4000.
14. Beharry S, Ackerley C, Corey M, et al. Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. Am J Physiol Gastrointest Liver Physiol 2007; 292: G839-48. (Pubitemid 46440393)
15. Blanco PG, Zaman MM, Junaidi O, et al. Induction of colitis in cftr-/- mice results in bile duct injury. Am J Physiol Gastrointest Liver Physiol 2004; 287: G491-6. (Pubitemid 38955270)
16. Pall H, Zaman MM, Andersson C, Freedman SD,. Decreased peroxisome proliferator activated receptor alpha is associated with bile duct injury in cystic fibrosis transmembrane conductance regulator-/- mice. J Pediatr Gastroenterol Nutr 2006; 42: 275-81.
17. Serhan CN, Arita M, Hong S, Gotlinger K,. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids 2004; 39: 1125-32. (Pubitemid 40129055)
18. Ludwig J, Dickson ER, McDonald GS,. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978; 379: 103-12. (Pubitemid 8388145)
19. Stanich PP, Bjornsson E, Gossard AA, Enders F, Jorgensen R, Lindor KD,. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis 2011; 43: 309-13.
20. Ollero M, Junaidi O, Zaman MM, et al. Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/- mice. J Cell Physiol 2004; 200: 235-44. (Pubitemid 38880207)
21. Seki H, Sasaki T, Ueda T, Arita M,. Resolvins as regulators of the immune system. ScientificWorldJournal 2010; 10: 818-31.
22. Calder PC,. Polyunsaturated fatty acids, inflammation, and immunity. Lipids 2001; 36: 1007-24. (Pubitemid 33065203)
23. Wall R, Ross RP, Fitzgerald GF, Stanton C,. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev 2010; 68: 280-9.